Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Aminosalicylic acid
Drug ID BADD_D00114
Description An antitubercular agent often administered in association with isoniazid. The sodium salt of the drug is better tolerated than the free acid.
Indications and Usage For the treatment of tuberculosis
Marketing Status Prescription; Discontinued
ATC Code J04AA01
DrugBank ID DB00233
KEGG ID D00162
MeSH ID D010131
PubChem ID 4649
TTD Drug ID D01WJL
NDC Product Code 49938-107; 76003-0710
Synonyms Aminosalicylic Acid | Acid, Aminosalicylic | 4-Aminosalicylic Acid | 4 Aminosalicylic Acid | para-Aminosalicylic Acid | para Aminosalicylic Acid | p-Aminosalicylic Acid | p Aminosalicylic Acid | p-Aminosalicylic Acid Monolithium Salt | p Aminosalicylic Acid Monolithium Salt | p-Aminosalicylic Acid Monopotassium Salt | p Aminosalicylic Acid Monopotassium Salt | Rezipas | p-Aminosalicylic Acid, Aluminum (2:1) Salt | p-Aminosalicylic Acid, Calcium (2:1) Salt | p-Aminosalicylic Acid, Monosodium Salt, Dihydrate | Pamisyl | Alumino-4-Aminosalicylic Acid | Alumino 4 Aminosalicylic Acid | p-Aminosalicylic Acid Monosodium Salt | p Aminosalicylic Acid Monosodium Salt
Chemical Information
Molecular Formula C7H7NO3
CAS Registry Number 65-49-6
SMILES C1=CC(=C(C=C1N)O)C(=O)O
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Malabsorption14.02.01.004; 07.17.01.001--
Methaemoglobinaemia01.05.01.002--
Nausea07.01.07.001--
Nervous system disorder17.02.10.001--Not Available
Neuropathy peripheral17.09.03.003--Not Available
Non-Hodgkin's lymphoma16.35.01.001; 01.17.01.001--Not Available
Optic neuritis17.04.05.001; 10.04.10.002; 06.04.08.002--Not Available
Peptic ulcer07.04.07.001--Not Available
Pericarditis02.06.02.001--
Prothrombin level decreased13.01.02.010--Not Available
Pseudolymphoma01.09.01.016--Not Available
Purpura24.07.06.005; 23.06.01.004; 01.01.04.003--
Pyrexia08.05.02.003--
Rash23.03.13.001--Not Available
Skin disorder23.03.03.007--Not Available
Thrombocytopenia01.08.01.002--Not Available
Urethral disorder20.07.01.002--Not Available
Urinary tract disorder20.08.01.001--Not Available
Urticaria23.04.02.001; 10.01.06.001--
Vascular purpura24.07.06.011; 23.06.01.008; 01.01.04.007--Not Available
Vasculitis24.05.02.001; 10.02.02.006--
Vomiting07.01.07.003--
Weight decreased13.15.01.005--
Lymphatic disorder01.09.01.003--Not Available
Malnutrition14.03.02.004--Not Available
Decreased appetite14.03.01.005; 08.01.09.028--
Blood disorder01.05.01.004--Not Available
Tendon pain15.07.01.009--Not Available
Faeces soft07.01.03.008--Not Available
The 2th Page    First    Pre   2    Total 2 Pages